Sugi Predict

Sugi Predict / Compounds / SCHEMBL2080592

SCHEMBL2080592

SCHEMBL2080592

COC(=O)c1coc(-c2ccnc(NC(=O)OC(C)(C)C)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 7/20 0.43
▸ ATR Q13535 1/20 0.43
▸ TGFBR1 P36897 1/20 0.42
▸ PIK3C3 Q8NEB9 1/20 0.41
▸ AAK1 Q2M2I8 5/20 0.40
▸ GSK3B P49841 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ PSMB8 P28062 1/20 0.39
▸ LCLAT1 Q6UWP7 1/20 0.38
▸ SREBF2 Q12772 1/20 0.38
▸ DAPK1 P53355 2/20 0.38
▸ MKNK1 Q9BUB5 2/20 0.38
▸ MYLK2 Q9H1R3 2/20 0.38
▸ MKNK2 Q9HBH9 2/20 0.38
▸ BMP2K Q9NSY1 2/20 0.38
▸ CIT O14578 1/20 0.38
▸ DAPK3 O43293 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268286 1.00 IRAK4 (0.43) IRAK4ATRTGFBR1PIK3C3AAK1
SCHEMBL29505431 0.90 IRAK4 (0.44) IRAK4TGFBR1PIK3C3AAK1GSK3B
SCHEMBL13162322 0.90 IRAK4 (0.44) IRAK4TGFBR1PIK3C3AAK1GSK3B
SCHEMBL29613007 0.90 TGFBR1 (0.42) IRAK4TGFBR1PIK3C3AAK1GSK3B
SCHEMBL16698999 0.90 TGFBR1 (0.42) IRAK4TGFBR1PIK3C3AAK1GSK3B
SCHEMBL13270402 0.87 IRAK4 (0.42) IRAK4TGFBR1PIK3C3AAK1GSK3B
SCHEMBL13634380 0.85 TGFBR1 (0.48) IRAK4ATRTGFBR1PIK3C3AAK1
SCHEMBL3436663 0.84 IRAK4 (0.43) IRAK4TGFBR1AAK1HDAC1HDAC8
SCHEMBL27790484 0.82 TGFBR1 (0.42) IRAK4ATRTGFBR1PIK3C3AAK1
SCHEMBL27790485 0.81 TGFBR1 (0.43) IRAK4TGFBR1PIK3C3AAK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 — — US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 — — US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 — — US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 — — US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 — — EP disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 — — EP disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
CN-101426774-A Azolecarboxamide derivative ASTELLAS PHARMA INC (JP) 2009-05-06 — — CN disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 IRAK4 93/4885ATR 1997/4885TGFBR1 158/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 IRAK4 199/4885ATR 1570/4885TGFBR1 242/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 IRAK4 4/4885ATR 389/4885TGFBR1 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.